<DOC>
	<DOCNO>NCT00475072</DOCNO>
	<brief_summary>This study evaluate efficacy safety PEGASYS plus ribavirin male patient hemophilia A chronic hepatitis C. All patient receive PEGASYS 180 microgram s.c. weekly plus ribavirin 1000-1200mg p.o . daily ( depend body weight ) 48 week . Following treatment 24 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus Ribavirin Hemophiliac Patients With Chronic Hepatitis C .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>male patient , &gt; =18 year age ; hemophilia A ; chronic hepatitis C ; compensate liver disease . therapy systemic antiviral , antineoplastic immunomodulatory treatment &lt; =6 month start study drug ; hepatitis A , hepatitis B HIV infection ; chronic liver disease chronic hepatitis C .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>